ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021
Deaths Attributable to Cancer in the US Human Immunodeficiency Virus Population During 2001-2015.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed.
- Early antiretroviral therapy and long-term cancer risk in HIV: 9-year outcomes from the START randomized trial.BMC cancer · 2026Trial
- Cancer Screening Behaviors among People with HIV in the United States and the Role of Multi-Level Social and Economic Factors: A Systematic Review.Current epidemiology reports · 2026Article
- Availability of Cancer Screening Across HIV Treatment Sites in the IeDEA Consortium.International journal of cancer · 2026Article
- HIV infection and survival in Hodgkin lymphoma: a real-world analysis of a multicenter research network.JNCI cancer spectrum · 2026Article
- Sex- and age- specific lung cancer incidence and mortality among Medicaid beneficiaries with and without HIV, 2001-2015.BMC cancer · 2026Article
- CCR5-targeted allogeneic gamma-delta CD19 chimeric antigen receptor T cells for HIV-associated B cell-malignancy immunotherapy.Nature biomedical engineering · 2026Article
- Geospatial Access to CAR-T Clinical Trials for Non-Hodgkin Lymphoma for Persons With HIV.JAMA network open · 2026Article
- Cancer prevalence and prognosis among individuals living with HIV and AIDS in Turkey: Multicenter BUHASDER study.International journal of STD & AIDS · 2026Article
- The Changing Face of HIV-Associated Malignancies: Is this the Same in Turkey As Well?Current HIV research · 2026Article
- Trends in Cancer Diagnoses Among People Living with HIV: A 20-Year Retrospective Study from a Tertiary Center in Thailand.Journal of clinical medicine · 2025Article
- Concordance of cancer-associated cytokines and mitochondrial DNA deletions in individuals with hepatocellular carcinoma and people living with HIV in Ghana.BMC gastroenterology · 2025Article
- A national, multicenter, retrospective study of human immunodeficiency virus infection-associated lymphoma in China.Clinical and experimental medicine · 2025Article
- Article
- Shared genomic features of HIV+ diffuse large B-cell lymphoma in two African cohorts.Scientific reports · 2025Article
- HIV Integration into the PTEN Gene and Its Tumor Microenvironment Implications for Lung Cancer.Current oncology (Toronto, Ont.) · 2025Article
- Lymphoproliferations in People Living with HIV: Oncogenic Pathways, Diagnostic Challenges, and New Therapeutic Opportunities.Cancers · 2025Review
- Elevated Tumor Mutation Burden in Cancer Patients with Underlying HIV Infection: Data from the Oncology Research Information Exchange Network (ORIEN).Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- HIV and Non-HIV Patients Have Similar Rates of Neoplastic Findings on Screening Colonoscopy Within a Predominantly African American Cohort.Cancer medicine · 2025Article
- Inequities in palliative care delivery to patients with HIV and stage IV cancers in the United States (2004-2020).JNCI cancer spectrum · 2025Article
- Early Detection of Cancer and Precancerous Lesions in Persons With HIV Through a Comprehensive Cancer Screening Protocol.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
Abstract
backgroundAntiretroviral therapy (ART) has reduced mortality among people living with human immunodeficiency virus (HIV), but cancer remains an important cause of death. We characterized cancer-attributable mortality in the HIV population during 2001-2015.
methodsWe used data from population-based HIV and cancer registries in the United States (US). Cox proportional hazards regression models were used to estimate adjusted hazard ratios (HRs) associating cancer diagnoses with overall mortality, we could perhaps cut these words to accommodate the word limit. However readers will probably want to know what statistical adjustments were made to the model. Population-attributable fractions (PAFs) were calculated using these HRs and the proportion of deaths preceded by cancer. Cancer-specific PAFs and cancer-attributable mortality rates were calculated for demographic subgroups, AIDS-defining cancers (Kaposi sarcoma [KS], non-Hodgkin lymphoma [NHL], cervical cancer), and non-AIDS-defining cancers.
resultsCancer-attributable mortality was 386.9 per 100 000 person-years, with 9.2% and 5.0% of deaths attributed to non-AIDS-defining and AIDS-defining cancers, respectively. Leading cancer-attributable deaths were from NHL (3.5%), lung cancer (2.4%), KS (1.3%), liver cancer (1.1%), and anal cancer (0.6%). Overall, cancer-attributable mortality declined from 484.0 per 100 000 person-years during 2001-2005 to 313.6 per 100 000 person-years during 2011-2015, while the PAF increased from 12.6% to 17.1%; the PAF for non-AIDS-defining cancers increased from 7.2% to 11.8% during 2011-2015. Cancer-attributable mortality was highest among those aged ≥60 years (952.2 per 100 000 person-years), with 19.0% of deaths attributed to non-AIDS-defining cancers.
conclusionsAlthough cancer-attributable mortality has declined over time, it remains high and represents a growing fraction of deaths in the US HIV population. Mortality from non-AIDS-defining cancers may rise as the HIV population ages. ART access, early cancer detection, and improved cancer treatment are priorities for reducing cancer-attributable mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.